CRANBURY, N.J., Dec. 29, 2016 /PRNewswire/ --
WHAT: Cornerstone Pharmaceuticals will present to
investors and biopharmaceutical executives from around the world.
The 9th Annual Conference Biotech Showcase™ is one of
the largest annual healthcare conferences around the world and will
take place in San Francisco
concurrently to the J.P. Morgan 35th Annual Healthcare
Conference. Members of Cornerstone's management team will present
information on its Altered Energy Metabolism Directed (AEMD)
platform, update on clinical trials for its lead compound CPI-613,
and future strategy.
Interviews prior and during the conference available upon
request:
- Presenters:
- Sanjeev Luther, Chief
Operating Officer, Cornerstone Pharmaceuticals
- Timothy S. Pardee, MD,
PhD, Chief Oncologist, Cornerstone Pharmaceuticals
- Board Members:
- Howard Jonas, Chairman of
the Board, Cornerstone Pharmaceuticals
- Jean-Pierre Sommadossi, PhD, Principal Founder, Chairman
and CEO of Atea Pharmaceuticals, Vice Chairman of Cornerstone
Pharmaceuticals Board of Directors
WHERE: 9th Annual Conference Biotech Showcase,
Hilton San Francisco Union Square, San
Francisco, California
WHEN: January 11, 2017,
2:30 – 3:00pm PT
CONTACT: Kara Golub,
609-456-0822 or kgolub@jfkhealth.com, for more
information.
About Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. is a privately held,
clinical-stage, oncology-focused pharmaceutical company committed
to the development and commercialization of therapies that exploit
the metabolic differences between normal cells and cancer cells.
The company's investors include IDT Corporation (NYSE: IDT).
Cornerstone's primary objective is to develop highly selective and
effective agents with minimal toxic effects on normal cells and
tissues. Cornerstone's first-in-class clinical lead compound,
CPI-613 is being evaluated in multiple Phase I, I/II, and II
clinical studies. The U.S. Food and Drug Administration (FDA) has
designated CPI-613 an orphan drug for the treatment of acute
myeloid leukemia (AML), pancreatic cancer and myelodysplastic
syndromes (MDS). www.cornerstonepharma.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cornerstone-pharmaceuticals-to-present-at-9th-annual-biotech-showcase-in-san-francisco-january-9-11-2017-300384099.html
SOURCE Cornerstone Pharmaceuticals, Inc.